These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

163 related articles for article (PubMed ID: 38473991)

  • 21. Enhancer of zeste homolog 2 promotes the proliferation and invasion of epithelial ovarian cancer cells.
    Li H; Cai Q; Godwin AK; Zhang R
    Mol Cancer Res; 2010 Dec; 8(12):1610-8. PubMed ID: 21115743
    [TBL] [Abstract][Full Text] [Related]  

  • 22. PRC2-complex related dysfunction in overgrowth syndromes: A review of EZH2, EED, and SUZ12 and their syndromic phenotypes.
    Cyrus S; Burkardt D; Weaver DD; Gibson WT
    Am J Med Genet C Semin Med Genet; 2019 Dec; 181(4):519-531. PubMed ID: 31724824
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Inhibition of EZH2 enhances the therapeutic effect of 5-FU via PUMA upregulation in colorectal cancer.
    Tan X; Zhang Z; Liu P; Yao H; Shen L; Tong JS
    Cell Death Dis; 2020 Dec; 11(12):1061. PubMed ID: 33311453
    [TBL] [Abstract][Full Text] [Related]  

  • 24. EZH2 is a potential therapeutic target for H3K27M-mutant pediatric gliomas.
    Mohammad F; Weissmann S; Leblanc B; Pandey DP; Højfeldt JW; Comet I; Zheng C; Johansen JV; Rapin N; Porse BT; Tvardovskiy A; Jensen ON; Olaciregui NG; Lavarino C; Suñol M; de Torres C; Mora J; Carcaboso AM; Helin K
    Nat Med; 2017 Apr; 23(4):483-492. PubMed ID: 28263309
    [TBL] [Abstract][Full Text] [Related]  

  • 25. The polycomb group protein SUZ12 regulates histone H3 lysine 9 methylation and HP1 alpha distribution.
    de la Cruz CC; Kirmizis A; Simon MD; Isono K; Koseki H; Panning B
    Chromosome Res; 2007; 15(3):299-314. PubMed ID: 17406994
    [TBL] [Abstract][Full Text] [Related]  

  • 26. The histone H3K27 methylation mark regulates intestinal epithelial cell density-dependent proliferation and the inflammatory response.
    Turgeon N; Blais M; Delabre JF; Asselin C
    J Cell Biochem; 2013 May; 114(5):1203-15. PubMed ID: 23192652
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Inhibition of the Histone Methyltransferase EZH2 Enhances Protumor Monocyte Recruitment in Human Mesothelioma Spheroids.
    Mola S; Pinton G; Erreni M; Corazzari M; De Andrea M; Grolla AA; Martini V; Moro L; Porta C
    Int J Mol Sci; 2021 Apr; 22(9):. PubMed ID: 33922336
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Ubiquitous expressed transcript promotes tumorigenesis by acting as a positive modulator of the polycomb repressive complex 2 in clear cell renal cell carcinoma.
    Zeng J; Xiang W; Zhang Y; Huang C; Chen K; Chen Z
    BMC Cancer; 2019 Sep; 19(1):874. PubMed ID: 31481081
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Identification of catalytic and non-catalytic activity inhibitors against PRC2-EZH2 complex through multiple high-throughput screening campaigns.
    Zhou Y; Du DH; Wang J; Cai XQ; Deng AX; Nosjean O; Boutin JA; Renard P; Yang DH; Luo C; Wang MW
    Chem Biol Drug Des; 2020 Oct; 96(4):1024-1051. PubMed ID: 32394628
    [TBL] [Abstract][Full Text] [Related]  

  • 30. MicroRNA-323-3p regulates the activity of polycomb repressive complex 2 (PRC2) via targeting the mRNA of embryonic ectoderm development (Eed) gene in mouse embryonic stem cells.
    Zhang Y; Teng F; Luo GZ; Wang M; Tong M; Zhao X; Wang L; Wang XJ; Zhou Q
    J Biol Chem; 2013 Aug; 288(33):23659-65. PubMed ID: 23821546
    [TBL] [Abstract][Full Text] [Related]  

  • 31. High histone acetylation and decreased polycomb repressive complex 2 member levels regulate gene specific transcriptional changes during early embryonic stem cell differentiation induced by retinoic acid.
    Lee ER; Murdoch FE; Fritsch MK
    Stem Cells; 2007 Sep; 25(9):2191-9. PubMed ID: 17525233
    [TBL] [Abstract][Full Text] [Related]  

  • 32. EZH2 Inhibition Sensitizes IDH1R132H-Mutant Gliomas to Histone Deacetylase Inhibitor.
    Sprinzen L; Garcia F; Mela A; Lei L; Upadhyayula P; Mahajan A; Humala N; Manier L; Caprioli R; Quiñones-Hinojosa A; Casaccia P; Canoll P
    Cells; 2024 Jan; 13(3):. PubMed ID: 38334611
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Discovery of a Novel Covalent EZH2 Inhibitor Based on Tazemetostat Scaffold for the Treatment of Ovarian Cancer.
    Zhang Q; Chen X; Cao J; Yang W; Wan G; Feng Q; Zhou S; Yang H; Wang N; Liu Z; Xiao H; Zhu Y; Yu L
    J Med Chem; 2023 Feb; 66(3):1725-1741. PubMed ID: 36692394
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Flow-dependent epigenetic regulation of IGFBP5 expression by H3K27me3 contributes to endothelial anti-inflammatory effects.
    Xu S; Xu Y; Yin M; Zhang S; Liu P; Koroleva M; Si S; Little PJ; Pelisek J; Jin ZG
    Theranostics; 2018; 8(11):3007-3021. PubMed ID: 29896299
    [No Abstract]   [Full Text] [Related]  

  • 35. Non-canonical transcriptional regulation of INHAT subunit SET/TAF-Iβ by EZH2.
    Hwang IJ; Park J; Seo SB
    Biochem Biophys Res Commun; 2022 Dec; 635():136-143. PubMed ID: 36274363
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Recent strategies targeting Embryonic Ectoderm Development (EED) for cancer therapy: Allosteric inhibitors, PPI inhibitors, and PROTACs.
    Zhao Y; Guan YY; Zhao F; Yu T; Zhang SJ; Zhang YZ; Duan YC; Zhou XL
    Eur J Med Chem; 2022 Mar; 231():114144. PubMed ID: 35093670
    [TBL] [Abstract][Full Text] [Related]  

  • 37. The H3K36me2 Methyltransferase Nsd1 Demarcates PRC2-Mediated H3K27me2 and H3K27me3 Domains in Embryonic Stem Cells.
    Streubel G; Watson A; Jammula SG; Scelfo A; Fitzpatrick DJ; Oliviero G; McCole R; Conway E; Glancy E; Negri GL; Dillon E; Wynne K; Pasini D; Krogan NJ; Bracken AP; Cagney G
    Mol Cell; 2018 Apr; 70(2):371-379.e5. PubMed ID: 29606589
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Anti-leukemic effects of HDACi Belinostat and HMTi 3-Deazaneplanocin A on human acute promyelocytic leukemia cells.
    Valiulienė G; Stirblytė I; Jasnauskaitė M; Borutinskaitė V; Navakauskienė R
    Eur J Pharmacol; 2017 Mar; 799():143-153. PubMed ID: 28192098
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Structural basis of oncogenic histone H3K27M inhibition of human polycomb repressive complex 2.
    Justin N; Zhang Y; Tarricone C; Martin SR; Chen S; Underwood E; De Marco V; Haire LF; Walker PA; Reinberg D; Wilson JR; Gamblin SJ
    Nat Commun; 2016 Apr; 7():11316. PubMed ID: 27121947
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Polycomb Repressive Complex 2 in Oncology.
    Guo Y; Yu Y; Wang GG
    Cancer Treat Res; 2023; 190():273-320. PubMed ID: 38113005
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 9.